Work

Development of Benzimidazole-Based BZ-30 as an Orally Bioavailable Broad-Spectrum Inhibitor of SARS-CoV-2

Year: 2026

Type: article

Source: Journal of Medicinal Chemistry

DOI: 10.1021/acs.jmedchem.6c00365

Authors: Simran Kaur, Deshkanwar S. Brar, Akshay Joshi, Nittu Singh, Ravneet S. Chawla, Sahil Kumar, Sumit Dhiman, Utpal Nandi, Rajesh P. Ringe, Krishan G. Thakur, Vinod D. Chaudhari

Institutions: Institute of Microbial Technology, Council of Scientific and Industrial Research, Academy of Scientific and Innovative Research, Indian Institute of Integrative Medicine

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Council of Scientific and Industrial Research, India, University Grants Commission, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India, CSIR - Institute of Microbial Technology

Awards: G1936269620, G6319249658

OpenAlex ID: W7154177378

FWCI:

Cites: 44

Cited by:

Related to: